Prognostic factors in multiple myeloma and the impact of the bone involvement


  • Flora Palmari Audi Oliveira
  • Vitória Melina Faquini de Souza
  • Maura Lima Pereira Bueno
  • Fernanda Marconi Roversi



Multiple myeloma, Hematological malignancy, Bone involvement


Background: Multiple myeloma is characterized by abnormal plasmocytes proliferation in the bone marrow, resulting in an immunoglobulin oversecretion, which can cause bone pain, anemia, kidney dysfunction, and infections. The present study evaluates prognostic factors and the bone involvement in patients who had a confirmed diagnosis of MM.

Methods: A retrospective study was conducted in hospital universitário São Francisco of Bragança Paulista. Patient demographic data, laboratory parameters and treatment received were recorded. We also analyzed the variables related to diagnosis and the development of bone lesions in MM patients.

Results: A total of 42 patients had a confirmed diagnosis of MM, out of which most (54.76%) were older than 65. Most patients (45.24%) had beta-2-microglobulin values greater than 5.5 mcg/dl, indicating an advanced stage of the disease and consequently a less favorable prognosis. The main clinical manifestation observed was anemia in 61.90% (26/42) and bone lesions 59.52% (25/42). The analysis of imaging exams showed that most patients presented bone alterations, such as osteopenia, lytic lesions and fractures. Interestingly, 11.90% patients were submitted to autologous bone marrow transplantation with further remission of the disease. Bone marrow transplantation increases overall survival and disease-free survival when compared to conventional treatment.

Conclusions: Since MM prognostic factors are numerous and, therefore, the understanding and analysis of the clinical and laboratory features of MM can contribute to an early diagnosis of patients, a targeted therapeutic approach and better outcomes.


Metrics Loading ...


Hengeveld PJ, Kersten MJ. B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?. Blood Cancer J. 2015;5:e282.

Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-60.

Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 2018;8(1):7.

Riley LK, Rupert J. Evaluation of Patients with Leukocytosis. Am Fam Physician. 2015;92(11): 1004-11.

Fu R, Gao S, Peng F, Li J, Liu H, Wang H, et al. Relationship between abnormal osteoblasts and cellular immunity in multiple myeloma. Cancer Cell Int. 2014;14:62.

Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol. 2013;31(18):2347-57.

Walk JC, Ayati BP, Holstein SA. Modeling the effects of multiple myeloma on kidney function. Sci Rep. 2019;9(1):1726.

Bhowmik D, Hines DM, Intorcia M, Wade RL. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database. J Med Econ. 2018; 21(6):622-8.

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-48.

Karampinos DC, Ruschke S, Dieckmeyer M, Diefenbach M, Franz D, Gersing AS, et al. Quantitative MRI and spectroscopy of bone marrow. J Magn Reson Imaging. 2018;47(2):332-53.

Aita MHC, Arantes LC, Silva JEP. Comparison between immunofixation and electrophoresis for the early detection of relapsed multiple myeloma. J Bras Patol Med Lab. 2015;51(6):356-9.

Tietsche de Moraes Hungria V, Allen S, Kampanis P, Soares EM. Serum free light chain assays not total light chain assays are the standard of care to assess monoclonal Gammopathies. Rev Bras Hematol Hemoter. 2016;38(1):37-43.

Fairfield H, Falank C, Avery L, Reagan MR. Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci. 2016;1364:32-51.

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863-9.

Kastritis E, Kastritis E, Roussou M. Evaluation of the revised international staging system in an independent cohort of unselected patients with multiple myeloma. Haematologica. 2017;102:593-9.

Tandon N, Rajkumar SV, LaPlant B, Pettinger A, Lacy MQ, Dispenzieri A, et al. Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. Blood Cancer J. 2017;7(2):e528.

Willan J, Eyre TA, Sharpley F, Watson C, King AJ, Ramasamy K. Multiple myeloma in the very elderly patient: challenges and solutions. Clin Interv Aging. 2016;11:423-35.

Branagan A, Lei M, Lou U, Raje N. Current treatment strategies for multiple myeloma. JCO Oncol Pract. 2020;16(1):5-14.

Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016; 43(6):676-81.

Derman BA, Reiser J, Basu S, Paner A. Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma. Int J Nephrol. 2018;2018:4654717.

Li L, Wang L. Multiple myeloma: what do we do about immunodeficiency?. J Cancer. 2019;10(7): 1675-84.

Michels TC, Petersen KE. Multiple myeloma: diagnosis and treatment. Am Fam Physician. 2017; 95(6):373-83.

Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24(6):vi133-7.

Wang S, Xu L, Feng J, Liu Y, Liu L, Wang J, et al. Prevalence and Incidence of multiple myeloma in urban area in china: a national population-based analysis. Front Oncol. 2019;9:1513.

Marino S, Roodman GD. Multiple myeloma and bone: the fatal interaction. Cold Spring Harb Perspect Med. 2018;8(8):29-35.

Buege MJ, Do B, Lee HC, Weber DM, Horowitz SB, Feng L, et al. Corrected calcium versus ionized calcium measurements for identifying hypercalcemia in patients with multiple myeloma. Cancer Treat Res Commun. 2019;21:100159.

Alanazi F, Kwa FAA, Burchall G, Jackson DE. New generation drugs for treatment of multiple myeloma. Drug Discov Today. 2020;25(2):367-79.

Knauf W, Aldaoud A, Hutzschenreuter U, Klausmann M, Dille S, Wetzel N, et al. Survival of non-transplant patients with multiple myeloma in routine care differs from that in clinical trials-data from the prospective German tumour registry lymphatic neoplasms. Ann Hematol. 2018;97(12): 2437-45.






Original Research Articles